Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENTPD5 | O75356 | 1/20 | 0.41 |
| ▸ | SOD1 | P00441 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | POLA1 | P09884 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25761977 | 0.86 | CYP3A4 (0.41) | POLA1 | |
| SCHEMBL23995452 | 0.81 | OPRD1 (0.41) | OPRD1 | |
| SCHEMBL10046369 | 0.80 | PIK3CB (0.35) | ENTPD5OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL10046367 | 0.80 | PIK3CB (0.35) | ENTPD5OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL10046374 | 0.80 | PIK3CB (0.35) | ENTPD5OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL10046373 | 0.80 | PIK3CB (0.35) | ENTPD5OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL10046131 | 0.80 | PIK3CB (0.35) | ENTPD5OPRM1PTPN1HIF1AEPAS1 | |
| SCHEMBL12234038 | 0.80 | ENTPD5 (0.63) | ENTPD5SOD1PTPN1HIF1AEPAS1 | |
| SCHEMBL12234034 | 0.80 | ENTPD5 (0.63) | ENTPD5SOD1PTPN1HIF1AEPAS1 | |
| SCHEMBL12234033 | 0.80 | ENTPD5 (0.63) | ENTPD5SOD1PTPN1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174571-A1 | METHOD OF TREATING SHIP1-MEDIATED DISEASES USING PELOROL DERIVATIVES | ZEBRAPEUTICS INC. (CA) | 2023-06-08 | — | — | US | disclosed |
| WO-2021213393-A1 | METHOD OF TREATING SHIP1-MEDIATED DISEASES USING PELOROL DERIVATIVES | ZEBRAPEUTICS INC. (CA) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174571-A1 | METHOD OF TREATING SHIP1-MEDIATED DISEASES USING PELOROL DERIVATIVES | PPM1D, PPM1F, PELI1 | ENTPD5 1879/4885SOD1 2872/4885OPRM1 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.